DURECT Corporation (DRRX): Price and Financial Metrics
DURECT Corporation (DRRX)
Today's Latest Price: $1.77 USD
Updated Sep 25 4:00pm
Add DRRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 233 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
DRRX Stock Summary
- DRRX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 189.11 -- higher than 83.62% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for DRRX is currently 315.29, higher than 98.97% of US stocks with positive operating cash flow.
- Revenue growth over the past 12 months for Durect Corp comes in at 153.13%, a number that bests 96.25% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Durect Corp, a group of peers worth examining would be EXEL, ESPR, TNAV, CRUS, and SMCI.
- DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Stock Price Chart Technical Analysis Charts
DRRX Price/Volume Stats
| Current price | $1.77 | 52-week high | $3.95 |
| Prev. close | $1.65 | 52-week low | $0.95 |
| Day low | $1.65 | Volume | 893,313 |
| Day high | $1.80 | Avg. volume | 1,437,713 |
| 50-day MA | $1.98 | Dividend yield | N/A |
| 200-day MA | $2.08 | Market Cap | 355.02M |
DURECT Corporation (DRRX) Company Bio
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $1.77 | $0.02 | -99% |
We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Durect Corp, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 0.23; that's higher than only 24.31% of US stocks in the Healthcare sector that have positive free cash flow.
- Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -99% |
| 1% | -99% |
| 2% | -99% |
| 3% | -98% |
| 4% | -98% |
| 5% | -98% |
Want more companies with a valuation profile/forecast similar to that of Durect Corp? See DRAD, AGHC, ALC, AMRN, and FGEN.
Loading social stream, please wait...